Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143

INTRODUCTION: NEAT001/ANRS143 was an open-label, randomized, non-inferiority study comparing raltegravir+darunavir/r(RGV+DRV/r) vs. tenofovir/emtricitabine+darunavir/r (TDF/FTC+DRV/r) in HIV-infected antiretroviral naïve adults. Primary efficacy outcome was a composite of virological and clinical ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Berenguer, Juan, Wit, Ferdinand, Jansson, Per O, Schwimmer, Christine, Kowalska, Justyna D, Saillard, Juliette, Diallo, Alpha, Pozniak, Anton L, Raffi, François, Grarup, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P040
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224823/
https://www.ncbi.nlm.nih.gov/pubmed/25394079
http://dx.doi.org/10.7448/IAS.17.4.19572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224823/
https://www.ncbi.nlm.nih.gov/pubmed/25394079
http://dx.doi.org/10.7448/IAS.17.4.19572

Ejemplares similares